Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 30, 2022 4:21pm
114 Views
Post# 35197708

RE:Midatech at $1.0475

RE:Midatech at $1.0475With US$20 million cash plus any cash from licensing deals and/or strategic partnerships Biodexa has enough of a cash runway to reach key hard catalysts. We need to start pricing in these catalysts over the next 18 months given the cash runway. What's a 10-15-20% chance at $12 billion given the market value of the lead clinical/near clinical programs? Additionally, what's the value of Q-Sphera/xB3 validated by the world's largest healthcare company and Chiesi, etc.? As the CEO of Biodexa stated he defies anyone to find a greater opportunity set in biotech for a company this size!

This is a SALTARELLI!
Armistice and Ladenberg Thalmann are on board!


Boomskid wrote: That means that V.BTI's value, as caculated by the terms of the deal, is now about 5.2¢

If U.MTP keeps that up it will be worth it to buy Bioasis instead of MTP.

Hard to imagine 6¢ these days.

jd


<< Previous
Bullboard Posts
Next >>